Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Peptide to Inhibit CD200 for Oncology by OX2 Therapeutics for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Peptide to Inhibit CD200 for Oncology is under clinical development by OX2 Therapeutics and currently in Phase I for Pediatric...
Peptide to Inhibit CD200 for Oncology by OX2 Therapeutics for High-Grade Glioma: Likelihood of Approval
Peptide to Inhibit CD200 for Oncology is under clinical development by OX2 Therapeutics and currently in Phase I for High-Grade...
Peptide to Inhibit CD200 for Oncology by OX2 Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Peptide to Inhibit CD200 for Oncology is under clinical development by OX2 Therapeutics and currently in Phase I for Recurrent...